潜在性冠動脈疾患におけるアスピリン:パイロット無作為化比較試験 (ASCAD-P)
サブクリニカル冠動脈疾患におけるアスピリン:パイロット無作為化比較試験
In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.
調査の概要
詳細な説明
Cardiovascular disease remains the leading cause of mortality worldwide. Recent large randomized trials have demonstrated limited net clinical benefit of aspirin in unselected primary prevention populations, leading to guideline recommendations against its systematic routine use for cardiovascular protection.
Patients with subclinical coronary artery disease represent a high-risk subgroup. These individuals have documented coronary artery disease but have not experienced overt cardiovascular events or undergone revascularization. Observational data suggest that this population carries a substantially increased risk of myocardial infarction compared with individuals without coronary atherosclerosis. However, the benefit-risk balance of aspirin in this intermediate-risk group remains uncertain
Primary Objective:
To evaluate the recruitment rate of a pilot randomized trial comparing low-dose aspirin prescription versus no prescription.
Secondary Objectives
To evaluate key feasibility metrics, including:
- The proportion of eligible patients who are randomized;
- Adherence and persistence to the assigned intervention at 12 months;
- The proportion of patients who do not complete the 12-month follow-up;
- Barriers to recruitment, adherence, and retention.
Exploratory Objectives:
To explore clinical outcomes at 12 months, including:
- The incidence of clinically significant bleeding events (BARC type 2, 3, or 5) and bleeding site;
- The incidence of major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization;
- Individual components of the composite endpoint;
- Cardiovascular mortality;
- Adverse Events and Serious Adverse Events.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Cyril Gagnon, MD
- 電話番号:2698 514-376-3330
- メール:cyril.gagnon@umontreal.ca
研究連絡先のバックアップ
- 名前:Samara Bloom, MSc
- 電話番号:2698 514-376-3330
- メール:samara.bloom@icm-mhi.org
研究場所
-
-
Quebec
-
Montreal、Quebec、カナダ、H1T 1C8
- 募集
- Montreal Heart Institute
-
主任研究者:
- Guillaume Marquis-Gravel, MD, MSc
-
コンタクト:
- Cyril Gagnon, MD
- 電話番号:2698 514-376-3330
- メール:cyril.gagnon@umontreal.ca
-
コンタクト:
- Samara Bloom, MSc
- 電話番号:2698 514-376-3330
- メール:samara.bloom@icm-mhi.org
-
主任研究者:
- Pierre Elias, MD
-
主任研究者:
- Cyril Gagnon, MD
-
主任研究者:
- Alino Demean Loghin, MD
-
Québec、Quebec、カナダ、G1V 4G5
- まだ募集していません
- Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
-
主任研究者:
- Tomas Cieza, MD
-
主任研究者:
- Roubie Dib, MD
-
コンタクト:
- Roubie Dib, MD
- 電話番号:(418) 656-8711
- メール:roubie.dib.1@ulaval.ca
-
コンタクト:
- Sara Desjardins, MD
- 電話番号:(418) 656-8711
- メール:sara.desjardins.2@ulaval.ca
-
主任研究者:
- Sara Desjardins, MD
-
Trois-Rivières、Quebec、カナダ、G8Z 3R9
- まだ募集していません
- Centre hospitalier affilié universitaire régional (CHAUR)
-
主任研究者:
- Vincent Spagnoli, MD
-
コンタクト:
- Farzin Brian Haghighat
- 電話番号:(819) 697-3333
- メール:farzin.brian.haghighat@umontreal.ca
-
主任研究者:
- Farzin Brian Haghighat
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Documented coronary atherosclerosis, as defined by one of the following criteria:
- Coronary artery calcium (CAC) score > 0;
- Cardiac CT angiography (CCTA) / CoroScan: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery;
- Coronary angiography: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery; if performed, physiological coronary assessments (FFR, dPR, iFR, etc.) and intracoronary imaging (IVUS or OCT) must be negative for significant disease.
-
Willing and able to provide informed consent and comply with study procedures
Exclusion Criteria:
- History of myocardial infarction (MI), coronary revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial revascularization procedure;
- Current prescription or clear indication for aspirin, low-molecular-weight heparin (LMWH), direct oral anticoagulants, or any other antithrombotic medication;
- Clear contraindication to aspirin;
- History of significant bleeding within the past year;
- Severe illness with limited life expectancy (i.e., <5 years);
- Any condition that, in the investigator's judgment, would make participation unsafe for the patient.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Low-dose Aspirin Prescription
Aspirin 81 mg orally once daily prescription |
Aspirin 81 mg orally once daily |
|
他の:No Prescription
No prescription of aspirin 81 mg orally once daily |
No prescription of aspirin 81 mg orally once daily |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Monthly Recruitment Rate
時間枠:12 months following study enrollment initiation
|
Average monthly patient recruitment rate: 0 ≤ Mean rate (patients/month) < 2 = study not feasible; 2 ≤ Mean rate (patients/month) < 4 = study feasible with protocol modifications; ≥ 4 Mean rate (patients/month) = study feasible without major protocol modifications. |
12 months following study enrollment initiation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
募集、遵守、および患者維持の障壁
時間枠:募集から追跡調査終了まで(12ヶ月)
|
募集から追跡調査終了まで(12ヶ月)
|
|
|
Proportion of Eligible Patients Randomized
時間枠:12 months following study enrollment initiation
|
Proportion of eligible patients who are randomized: 0% ≤ Proportion < 30% = study not feasible, major protocol modifications required; 30% ≤ Proportion < 61% = study feasible with protocol modifications; ≥ 61% = study feasible without protocol modifications. |
12 months following study enrollment initiation
|
|
Intervention Adherence
時間枠:From randomization to the end of follow-up (12 months)
|
Proportion of days on which patients take the assigned intervention (adherence): 0% ≤ Mean proportion < 25% = study not feasible, major protocol modifications required; 25% ≤ Mean proportion < 74% = study feasible with protocol modifications; ≥ 74% = study feasible without protocol modifications. |
From randomization to the end of follow-up (12 months)
|
|
Intervention Persistence
時間枠:From randomization to end of follow-up (12 months)
|
Proportion of patients who still take the assigned intervention at 12 months of follow-up (persistence): 0% ≤ Proportion < 25% = study not feasible, major protocol modifications required; 25% ≤ Proportion < 70% = study feasible with protocol modifications; ≥ 70% = study feasible without protocol modifications. |
From randomization to end of follow-up (12 months)
|
|
Proportion of Patients Lost to Follow-up
時間枠:End of follow-up (12 months)
|
Proportion of patients who do not complete the 12-month follow-up visit: ≥ 10% = study not feasible, major protocol modifications required; 6% ≤ Proportion < 10% = study feasible with protocol modifications; 0% ≤ Proportion < 6% = study feasible without protocol modifications. |
End of follow-up (12 months)
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
出血率(BARC 2、3、5)
時間枠:登録から追跡終了(12ヶ月)まで
|
登録から追跡終了(12ヶ月)まで
|
|
|
有害事象(AE)率および重篤な有害事象(SAE)率
時間枠:登録から追跡調査終了(12か月)まで
|
登録から追跡調査終了(12か月)まで
|
|
|
Major Adverse Cardiovascular Event (MACE) Rate
時間枠:From enrollment to the end of follow-up (12 months)
|
MACE rate (all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization) at 12 months of follow-up |
From enrollment to the end of follow-up (12 months)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2026-3694
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。